Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis
Efficacy and Safety of Baricitinib in Different Doses for the Treatment of Moderate to Severe Rheumatoid Arthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Sadikul i sadik, MBBS
- Phone Number: +8801723674334
- Email: sadik48rmc@gmail.com
Study Locations
-
-
[Other]
-
Dhaka, [Other], Bangladesh, 1207
- Dr. Md. Sadikul islam
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age greater than 18 years
- patients fulfill the ACR/EULAR 2010 classification criteria for RA
- DAS-28 CRP more than 3.2 despite optimum dose of methotrexate
Exclusion Criteria:
- Recent or concurrent infection including active or latent tuberculosis except patients with latent tuberculosis in whom treatment was commenced ≥ 4 weeks before randomization
- Hemoglobin (Hb) < 8 g/dl
- White blood cell count < 4000, Neutrophil count < 1000, Platelet count < 100000/mm3
- Live vaccines within 3 months prior to the first dose
- Serum creatinine > upper limit of normal reference range
- eGFR < 60 ml/minute/1.73 m2
- Alanine transaminase (ALT) more than ULN
- Pregnant or breast feeding females of child-bearing potential
- Evidence or history of malignancy, with the exception of adequately treated or excised non-metastatic basal or squamous cell cancer of the skin or cervical carcinoma in situ
- New York Heart Association Class III and IV congestive heart failure
- Previous history of thromboembolism, deep venous thrombosis, diverticulitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Baricitinib 2mg and methotrexate 10mg
Baricitinib 2mg once daily plus methotrexate 10mg per week
|
baricitinib 4mg once daily in group A
Other Names:
|
|
Experimental: Baricitinib 4mg and methotrexate 10mg
Baricitinib 4mg once daily plus methotrexate 10mg per week
|
baricitinib 4 mg once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease activity score 28-C-reactive protein (DAS28-CRP)
Time Frame: 6 months
|
Disease activity score in 28 joints has to measure at 6 months.
score less than or equal 3.2 will be regarded as low disease activity
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease activity score 28-C-reactive protein (DAS28-CRP)
Time Frame: 6 months
|
Disease activity score in 28 joints has to measure at 6 months.
score less than or equal 3.2 will be regarded as low disease activity
|
6 months
|
|
Clinical Disease activity index (CDAI)
Time Frame: 6 months
|
clinical disease activity index at 6 months will be recorded.
Score of equal or less than 10 will be regarded as low disease activity
|
6 months
|
|
Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time Frame: 6 months
|
health assesment by HAQ-DI at 6 months will be recorded.
reduction of more than 0.22 will be regarded as improvement.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sadikul i sadik, MBBS, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Publications and helpful links
General Publications
- Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489.
- Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. Arthritis Rheumatol. 2017 Mar;69(3):506-517. doi: 10.1002/art.39953.
- Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88-95. doi: 10.1136/annrheumdis-2016-210094. Epub 2016 Sep 29. Erratum In: Ann Rheum Dis. 2017 Sep;76(9):1634.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BSMMU/2022/11646
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.